Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Post Marketing Surveillance

Post-Marketing Surveillance: Pharmacovigilance Planning and Signal Detection After Approval

The information obtainable from a pre-approval trial is inherently limited. Post-marketing surveillance exists because the full safety profile of a medicine becomes apparent only when substantially more people use it, over substantially longer periods.

Pubrica AcademyWritten by a pharmacovigilance reviewer Reviewed bya regulatory-writing reviewer Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources1 peer-reviewed

Post-marketing surveillance is the ongoing monitoring of a medicine's safety and effectiveness after it has been approved and is in routine clinical use, intended to detect rare, delayed, or population-specific adverse effects that pre-approval trials — limited in size, duration and population diversity — are not statistically positioned to find.

Learning objectives

  • Why pre-approval trials cannot detect every safety signal a medicine will eventually show.
  • The planning framework (pharmacovigilance planning) that structures post-approval safety monitoring.
  • What signal detection means and how it differs from signal confirmation.
  • What risk evaluation and mitigation strategies add beyond routine monitoring.

Common misconceptions

  • “Approval means a medicine's safety profile is fully known.” Approval reflects what a trial of necessarily limited size, duration and population diversity could detect; rare or delayed effects, and effects in populations underrepresented in trials, often only become visible once far larger numbers of people have used the medicine.
  • “Post-marketing surveillance is passive reporting and nothing else.” Modern pharmacovigilance planning combines passive spontaneous-report systems with active surveillance methods, such as targeted cohort monitoring, specifically because passive reporting alone under-detects many real signals.

Limitations of pre-approval trials in detecting safety signals

A pre-approval trial programme is designed to detect the safety signals its sample size and duration can statistically support; a reaction occurring in one in ten thousand patients, or only after years of use, or disproportionately in a population underrepresented in the trial population, is often mathematically unlikely to appear before approval. The ICH E2E guideline on pharmacovigilance planning, developed by the International Council for Harmonisation, frames post-approval safety monitoring as a necessary continuation of safety characterisation precisely for this reason — the safety profile understood at approval is explicitly provisional, not final.

Pharmacovigilance planning as a structured framework

ICH E2E sets out a structured approach to planning post-approval safety monitoring, built around a safety specification (an explicit summary of what is known, and what remains unknown or uncertain, about a medicine's safety at the time of approval) and a pharmacovigilance plan that specifies which monitoring methods — routine spontaneous reporting, enhanced passive surveillance, active surveillance through registries or cohort studies, or additional post-approval studies — will be used to address each identified or potential risk. The framework is explicit that the choice of method should match the specific uncertainty being addressed, rather than defaulting to passive reporting for every risk regardless of how it is best detected.

Distinction between signal detection and signal confirmation

A pharmacovigilance signal is information suggesting a possible new or changed association between a medicine and an adverse event, strong enough to warrant further investigation — it is a hypothesis, not a conclusion. Detecting a signal (through disproportionality analysis of spontaneous reports, or through active surveillance data) is a distinct step from confirming it, which typically requires a targeted study designed to test the specific hypothesis the signal raised. Treating a detected signal as an already-confirmed causal finding, before that confirmatory step has been done, is one of the most common misreadings of post-marketing safety data.

Key points

Key points

Post-marketing surveillance exists because approval reflects what a necessarily limited pre-approval trial programme could detect, not a complete safety profile; a structured pharmacovigilance plan matches specific monitoring methods to specific known and potential risks, and a detected safety signal is a hypothesis requiring confirmation, not yet a conclusion.

Practical application

Practical application

  1. The safety specification should be established before monitoring methods are selected. What is known, and what remains uncertain, about the medicine’s safety at approval should be listed explicitly before it is decided which surveillance methods address which gaps.
  2. The monitoring method should be matched to the specific uncertainty. Active surveillance or targeted studies should be used for risks that passive spontaneous reporting is unlikely to detect reliably, rather than passive reporting being relied upon by default.
  3. A detected signal should be treated as a hypothesis rather than a finding. It should be stated explicitly when a safety signal has been detected but not yet confirmed, together with the confirmatory study that would be required before causal language is used.

Frequently asked questions

Pharmacovigilance is the broader discipline of detecting, assessing and preventing adverse effects of medicines across their lifecycle; post-marketing surveillance is specifically the post-approval monitoring component of it.

A safety specification identifying a known or potential risk that passive reporting is unlikely to characterise adequately typically triggers a pharmacovigilance plan with active surveillance or additional studies for that specific risk.

Regulatory action can follow from post-marketing signals, usually after some degree of confirmatory assessment, though the specific evidentiary threshold varies by regulator and by the severity of the signal.

References

  1. International Council for Harmonisation. ICH Harmonised Guideline E2E: Pharmacovigilance Planning. read 10 October 2026. View ICH E2E guideline (PDF)

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Post-Marketing Surveillance: Pharmacovigilance Planning and Signal Detection After Approval. Pubrica. https://pubrica.com/academy/concepts-definitions/post-marketing-surveillance/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Pharmacovigilance plan stub

Use when drafting a post-approval safety monitoring plan.

Known risks identified in safety specification: ____
Potential risks identified: ____
Missing information identified: ____
Monitoring method per risk (routine / enhanced passive / active / additional study): ____
Signal detection method(s) to be used: ____

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s pharmacovigilance team develops the safety specification and pharmacovigilance plan according to the ICH E2E structure, and reports signal detection and confirmation findings to the standard expected by regulators.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Structuring post-approval safety monitoring in accordance with ICH E2E

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.